Summaries for Blindness

Sources:
44Wikipedia, 22MalaCards
See all sources

Export this MalaCard
Wikipedia: Blindness is the condition of lacking visual perception due to physiological or neurological factors....44 more...

MalaCards: Blindness, also known as low vision nos finding, is related to retinitis and carcinoma. An important gene associated with Blindness is NYX (nyctalopin), and among its related pathways are Visual Cycle in Retinal Rods and Neuroactive ligand-receptor interaction. The compounds estrogen and serine have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and liver, and related mouse phenotypes are nervous system and homeostasis/metabolism.

Aliases & Descriptions for Blindness

Sources:
6Disease Ontology, 8DISEASES, 32Novoseek , 43UMLS, 40SNOMED-CT, 19ICD9CM
See all sources

Aliases & Descriptions:

blindness 6 8 32
low vision nos finding 6
blindness and low vis. 6
low vision nos 6
blind vision 43

External Ids:

ICD9CM19 369
SNOMED-CT40 267729001, 155146008, 155150001 193698004, more

Related Diseases for Blindness

Sources:
13GeneCards, 14GeneDecks
See all sources

Diseases related to blindness by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1129)
idRelated DiseaseScoreTop Affiliating Genes
1retinitis57.3ZNF513, PIK3C2A, PIK3CG, LRAT, LRP5, PDE4A
2carcinoma53.0PIK3C2A, PIK3CG, LRAT, LRP5, PDE4A, REN
3night blindness48.6ZNF513, LRAT, RDH5, RBP4, RBP3, SEMA4C
4prostatitis47.8PIBF1, PIK3C2A, PIK3CG, LRAT, LRP5, PDE4A
5hypertension47.8PIK3C2A, PIK3CG, LRP5, COG2, PDE4A, REN
6diabetes mellitus46.3PIK3C2A, PIK3CG, LRP5, COG2, PDE4A, REN
7obesity45.8PIK3C2A, PIK3CG, LRP5, COG2, REN, CNR1
8arthritis45.5PIBF1, PIK3CG, LRP5, PDE4A, CNBP, CNR1
9leukemia44.8PIBF1, PIK3C2A, PIK3CG, LRP5, COG2, PDE4A
10pancreatitis44.8PIK3C2A, PIK3CG, LRAT, LRP5, PDE4A, REN
11cholesterol43.9PIK3C2A, PIK3CG, LRAT, LRP5, COG2, REN
12rheumatoid arthritis43.6PIBF1, PIK3CG, LRP5, PDE4A, CNR1, CNTF
13cerebritis41.8PIK3C2A, PIK3CG, COG2, PDE4A, REN, CNR1
14alzheimer's disease41.7PIK3CG, LRAT, COG2, PDE4A, REN, CNR1
15myocardial infarction41.3PIK3C2A, PIK3CG, COG2, PDE4A, REN, CNR1
16malaria41.2PDE4A, REN, CNTF, VWF, RBP4, SELE
17schizophrenia41.2PIK3CG, PDE4A, CNR1, CNTF, SELE, SEPP1
18congenital stationary night blindness41.1ZNF81, ZNF41, RDH5, USP11, BHLHE23, SDK1
19asthma41.1PIK3CG, PDE4A, CNR1, SELE, SELP, SERPINA7
20atherosclerosis39.9PIK3C2A, PIK3CG, LRP5, COG2, PDE4A, REN
21fibrosis39.8PIK3CG, PDE4A, REN, CNR1, VWF, RBP4
22insulin resistance39.4PIK3CG, COG2, REN, CNBP, CNR1, CNTF
23retinal degeneration39.1LRAT, CNGB1, CNTF, RDH12, RDH5, RCVRN
24thyroiditis38.7PIK3C2A, PIK3CG, COG2, PDE4A, REN, VWF
25colorectal cancer38.1PIK3CG, LRP5, COG2, CNR1, VWF, RBP3
26acute myocardial infarction38.0PIK3C2A, PIK3CG, COG2, REN, CNTF, VWF
27retinal disease37.5CNGA3, CNTF, VWF, RDH5, RCVRN, RBP4
28multiple sclerosis37.4PDE4A, CNR1, CNTF, VWF, SELE, SELP
29anemia37.3REN, VWF, SELE, SELP, SERPINC1, SERPINA7
30type 2 diabetes mellitus37.3COG2, CNR1, VWF, GCG, RBP4, SELE
31ischemia37.1PIK3C2A, PIK3CG, COG2, PDE4A, REN, CNR1
32essential hypertension37.0COG2, REN, VWF, SELE, SELP, SERPINC1
33cystic fibrosis36.9PIK3CG, PDE4A, REN, VWF, RBP4, SELP
34hypoxia36.6PIK3C2A, PIK3CG, LRP5, PDE4A, REN, VWF
35pneumonia36.6PIK3C2A, COG2, PDE4A, RBP4, SELE, SERPINC1
36melanoma36.6PIK3C2A, PIK3CG, LRAT, PDE4A, CNTF, VWF
37tuberculosis36.4PIK3CG, RDH12, RDH5, SERPINC1, SERPINA7, VEGFA
38sepsis36.3PDE4A, RBP4, RBP3, SELE, SELP, SERPINC1
39color blindness36.3CNGA3, CNGB3, KIAA1109, MXD4, SAE1, XG
40alcoholism36.2CNR1, SCT, CFTR, GSR, IL1RN, MAPT
41thrombosis36.0PIK3C2A, PIK3CG, COG2, REN, VWF, SELE
42neuropathy35.9PIK3C2A, PDE4A, REN, CNR1, CNTF, VWF
43parkinson's disease35.7CNR1, CNTF, SERPINF1, KCNJ5, CHM, CHKB
44cortical blindness35.4MT-ND5, MT-ND4, MT-ND1, MT-ND6, ASPA, IFNA10
45osteoarthritis34.9PIK3CG, LRP5, PDE4A, CNR1, SERPINE1, VIP
46osteoporosis34.9LRP5, PDE4A, CNR1, GCG, RBP4, SELE
47hepatitis34.7RBP4, SELP, XDH, GUSB, GSR, IL2RB
48dermatitis34.6PIK3C2A, PDE4A, CNR1, SELE, SELP, VIP
49homocysteine34.4PIK3C2A, COG2, REN, VWF, GCG, SELE
50hypercholesterolemia34.2PIK3C2A, COG2, VWF, GCG, RBP4, SELE

Graphical network of the top 20 diseases related to blindness:



Graphical network of diseases related to blindness

Clinical Features for Blindness

Drugs & Therapeutics for Blindness

Sources:
4CenterWatch, 29NIH Clinical Center, 5ClinicalTrials, 43UMLS, 28NDF-RT
See all sources

Approved drugs:

Search CenterWatch for blindness

Drug clinical trials:

Search ClinicalTrials for blindness

Search NIH Clinical Center for blindness

Search CenterWatch for blindness

Genetic Tests for Blindness

Anatomical Context for Blindness

Sources:
22MalaCards
See all sources

MalaCards organs/tissues related to blindness:

22
Brain, Skin, Liver, Kidney, Lung, Spinal cord, Ovary, Bone marrow, Whole blood, Cortex, Retina, Heart, Skeletal muscle, Small intestine, Colon, Pancreas, Thyroid, Breast, Placenta, Prostate, Myeloid, Nk cells, T cells, B cells, Endothelial, Fetal brain, Fetal liver, Fetal lung, Bronchial epithelium, Fetal thyroid, Adrenal cortex, Pituitary

Phenotypes for genes affiliated with Blindness

Sources:
25MGI
See all sources

MGI Mouse Phenotypes related to blindness:

25 (show all 29)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1nervous system phenotypeMP:000363124.7LRAT, LRP5, PDE4A, REN, CNBP, CNGA3
2homeostasis/metabolism phenotypeMP:000537623.0PIK3C2A, PIK3CG, LRAT, LRP5, REN, CNR1
3vision/eye phenotypeMP:000539122.9LRAT, LRP5, CNBP, CNGA3, CNGB1, CNGB3
4growth/size phenotypeMP:000537818.2PIK3C2A, PIK3CG, REN, CNBP, CNGB1, CNR1
5cellular phenotypeMP:000538417.5PIK3CG, LRP5, CNBP, CNGB3, CNR1, CNTF
6cardiovascular system phenotypeMP:000538517.0PIK3CG, LRP5, PDE4A, REN, VWF, RBP4
7reproductive system phenotypeMP:000538916.6LRAT, REN, RBP4, SERPINF1, SEPP1, VIP
8immune system phenotypeMP:000538716.0LRP5, PDE4A, REN, CNTF, VWF, SELP
9normal phenotypeMP:000287315.2LRP5, REN, RBP4, SELE, VIP, VEGFA
10pigmentation phenotypeMP:000118614.4LRP5, SERPINC1, SEMA4C, SERPINF1, SEMA4A, MYO7A
11integument phenotypeMP:001077114.4PIK3CG, CNR1, SELP, SEMA4C, LIF, PBX1
12hematopoietic system phenotypeMP:000539714.3CNTF, SEMA4A, LCN2, LAG3, P2RY12, AVPR2
13no phenotypic analysisMP:000301213.5CNR1, VEGFA, MYOC, MYO7A, CLRN1, CLCN5
14endocrine/exocrine gland phenotypeMP:000537913.4LRP5, CLCN2, PAFAH1B1, CHRM3, XDH, FZD4
15liver/biliary system phenotypeMP:000537013.4LRP5, SERPINC1, SEPP1, VEGFA, LPL, LIF
16renal/urinary system phenotypeMP:000536713.4REN, SELP, RARA, CLU, CLCN5, PBX1
17embryogenesis phenotypeMP:000538012.9LRP5, CNBP, SERPINC1, BMP8B, PBX1, PAX6
18adipose tissue phenotypeMP:000537511.9PIK3C2A, CNR1, SERPINE1, LPL, LIF, LEP
19limbs/digits/tail phenotypeMP:000537111.4LRP5, SEPP1, VEGFA, VDR, RARA, PBX1
20muscle phenotypeMP:000536911.2PIK3CG, REN, CNTF, RBP4, VEGFA, LPL
21other phenotypeMP:000539511.0CNR1, VASP, RARA, CLU, PBX1, KDR
22tumorigenesisMP:00020068.5SERPINE1, RARA, PAX6, LEP, MT-ND6, B2M
23mortality/agingMP:0010768INFPIK3C2A, LRP5, REN, CNBP, CNGB1, CNR1
24behavior/neurological phenotypeMP:0005386INFLRP5, REN, CNGA3, CNR1, CNTF, PCDH15
25digestive/alimentary phenotypeMP:0005381INFVWF, GCG, SERPINF1, VEGFA, VDR, RARA
26respiratory system phenotypeMP:0005388INFSELP, LPL, LIF, PAX6, CHRM3, UCP2
27skeleton phenotypeMP:0005390INFPIK3CG, CNBP, CNR1, VEGFA, VDR, RARA
28hearing/vestibular/ear phenotypeMP:0005377INFPCDH15, VDR, MYO7A, RARA, USH1G, USH1C
29craniofacial phenotypeMP:0005382INFLRP5, CNBP, CLCN5, PBX1, PAX6, CFTR

Publications for genes affiliated with Blindness

Sources:
35PubMed
See all sources

Articles related to blindness:

(show top 50)    (show all 1321)
idTitleAuthorsYearAffiliating Genes
1GPR179 is required for depolarizing bipolar cell function and is mutated in autosomal-recessive complete congenital stationary night blindness. (22325362)Peachey N.S.... Gregg R.G.2012GPR179
2Establishing optimal selenium status: results of a ra ndomized, double-blind, placebo-controlled trial. (20181815)Hurst R.... Fairweather-Tait S.J.2010SEPP1
3A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. (19409038)Horti J.... Bodrogi I.2009EGFR
4Effects of grape seed extract in Type 2 diabetic subj ects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stres s and insulin sensitivity. (19646193)Kar P.... Cummings M.2009ALB, INS
5Postprandial ghrelin responses are associated with th e intermeal interval in time-blinded normal weight men, but not in obese men. (19385031)Blom W.A.... Hendriks H.F.2009GHRL
6Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. (19139391)Schmieder R.E.... van Ingen H.2009REN
7The effect of exogenous glucagon-like peptide-1 on th e glycaemic response to small intestinal nutrient in the critically ill: a rand omised double-blind placebo-controlled cross over study. (19439067)Deane A.M.... Horowitz M.2009GCG
8Parecoxib versus dipyrone (metamizole) for postoperat ive pain relief after hysterectomy : a prospective, single-centre, randomized, double-blind trial. (18544002)Soltesz S.... Molter G.2008PTGS2
9Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. (18358927)Yokota S.... Kishimoto T.2008CRP
10Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. (17919550)O'Farrell A.M.... Guler H.P.2007DPP4
11Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. (17576071)Fattouch K.... Ruvolo G.2007C1S
12A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. (17519075)Gottlieb A.B.... Mascelli M.A.2007IL8, IL18, IFNG
13Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. (16984383)Ueno H.... Okusaka T.2006LTF
14A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. (16630771)Zelber-Sagi S.... Oren R.2006INS
15Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. (15647778)Schram M.T.... Stehouwer C.D.2005ALB
16Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. (15925816)Polychronis A.... Coombes R.C.2005EGFR, ESR1, EREG
17Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double -blind, placebo-controlled trial. (15132403)Goldberg A.C.... Mitchel Y.B.2004APOB
18Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching. (15569037)Ajayi A.A.... Udoh S.J.2004OPRM1
19Effectiveness of salmon calcitonin nasal spray in the treatment of lumbar canal stenosis: a double-blind, randomized, placebo-controlled, parallel group trial. (15507793)Podichetty V.K.... Mazanec D.J.2004CALCA
20Circadian genes in a blind subterranean mammal III: molecular cloning and circadian regulation of cryptochrome genes in the blind subterranean mole rat, Spalax ehrenbergi superspecies. (14964701)Avivi A.... Nevo E.2004CRY1
21Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. (15598476)Derosa G.... Roggeri D.E.2004COG2
22The effect of mifepristone on the expression of steroid hormone receptors in human decidua and placenta: a randomized placebo-controlled double-blind study. (14671179)Chan C.C.... Cheung A.N.2003PGR, ESR1, NR3C1
23The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. (12691930)Sarr M.G.2003SST
24Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. (12742979)Gheorghiade M.... Orlandi C.2003AVPR2
25A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. (12946547)Derosa G.... Fogari R.2003SERPINE1, ALB
26A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. (12645718)Morales D.L.... Oz M.C.2003ACE
27Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast can cer. (12637464)Buzdar A.... Hudis C.2003ESR1
28Double-blind randomised trial comparing the non-stero idal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. (12488294)Tominaga T.... Ohashi Y.2003CYP19A1
29Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. (12734787)Chou K.H.... Spritzer P.M.2003SHBG
30A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. (11896309)Strauss R.G.... Stump D.C.2002F8
31A double-blind, randomized comparison of intramuscula rly and intravenously administered parecoxib sodium versus ketorolac and placeb o in a post-oral surgery pain model. (11519767)Daniels S.E.... Hubbard R.C.2001PTGS2
32Responder characteristics to a single oral dose of ch olinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. (11125238)Almkvist O.... Nordberg A.2001ACHE
33A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. (10681340)Suputtamongkol Y.... White N.J.2000PTAFR
34Short-chain fatty acid enemas stimulate plasminogen activator inhibitor-1 after abdominal aortic graft surgery: a double-blinded, placebo-controlled study. (10828475)Mortensen F.V.... Hessov I.2000SERPINE1
35Effect of the serotonin receptor agonist, buspirone, on immune function in HIV-infected individuals: a six-month randomized, double-blind, placebo-controlled trial. (11590486)Eugen-Olsen J.... Nielsen J.O.2000HTR3A
36Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. (10573067)Winston D.J.... Logan E.1999CSF3
37Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. (10399774)Asthana S.... Plymate S.R.1999IGFBP3
38The safety and efficacy of granulocyte-macrophage col ony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based an tiretroviral therapy: a randomized double-blind, placebo-controlled trial. (10479132)Skowron G.... Gilbert M.J.1999IL10
39Effects of metformin in patients with poorly controll ed, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, place bo-controlled trial. (10428734)AvilAcs-Santa L.... Raskin P.1999INS
40A randomized controlled double-blind study of the eff ects on hemostasis of two progestogen-only pills containing 75 microgram desoge strel or 30 microgram levonorgestrel. (9693398)Winkler U.H.... Coelingh Bennink H.J.1998PLAT, F2
41Loss-of-function mutations in a calcium-channel alpha 1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness. (9662400)Bech-Hansen N.T.... Boycott K.M.1998CACNA1F
42Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. (9722035)Eisele B.... Delvos U.1998SERPINC1
43Double-blind placebo-controlled study of oxatomide in the treatment of childhood asthma. (9066184)Chiu C.P.... Hsieh K.H.1997HRH1
44Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-convertin g enzyme inhibitor-induced cough. (9089428)Chan P.... Lee Y.S.1997ACE
45Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. (8823686)Lin M.K.... Pruzanski W.1996PLA2G2A
46Fosinopril versus enalapril in the treatment of hyper tension: a double-blind study in 195 patients. (8797128)Hansson L.... KjellstrAPm T.1996ACE
47Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. (8605790)Zeni F.... Bertrand J.C.1996TNF, IL6, IL8
48A controlled double blind study of azathioprine in th e management of Crohn's disease. (8549944)Candy S.... Goodman R.1995CRP
49The effect of ursodeoxycholic acid on serum enzymes a nd liver histology in patients with chronic active hepatitis. A 12-month double -blind, placebo-controlled trial. (7912249)Attili A.F.... Callea F.1994GGT1
50Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta. (1431312)Liberati A.M.... Grignani F.1992B2M, IL1A, IFNB1

Expression for genes affiliated with Blindness

Sources:
1BioGPS
See all sources
Expression patterns in normal tissues for genes affiliated with Blindness

Pathways for genes affiliated with Blindness

Sources:
36QIAGEN, 20KEGG, 38Reactome, 10EMD Millipore, 41Thomson Reuters
See all sources

Pathways related to blindness according to GeneDecks:

(show top 50)    (show all 74)
idPathwayScoreTop Affiliating Genes
1Visual Cycle in Retinal Rods3614.5LRAT, CNGA1, CNGA3, CNGB1, CNGB3, RDH12
2Neuroactive ligand-receptor interaction2014.3CNR1, LEP, CHRM3, CGA, AVPR2, FSHB
3cAMP Pathway3612.9CNGA1, CNGA3, CNGB1, CNGB3, GCG, CLCN2
4Activation of cAMP-Dependent PKA3612.5CNGA1, CNGA3, CNGB1, CNGB3, GCG, VASP
5G alpha (q) signalling events3812.3MLN, MLNR, CCKBR, CCK, GNRH1, GHRL
6CREB Pathway3612.2KDR, FGF10, FGF23, GRM6, IL2, IL2RA
7Rho Family GTPases3611.9LIF, KDR, CDH3, ITGAL, ITGAM, ARHGEF2
8Intracellular Calcium Signaling3611.8CNGA1, CNGA3, CNGB1, CNGB3, KDR, GUCY2D
9Cytokine-cytokine receptor interaction2011.6CNTF, VEGFA, LIF, KDR, LEP, CD40LG
10all-trans-Retinoic Acid Signaling in Brain3611.5RARA, LIF, IL10, IL11, IL18, IL1A
11ERK Signaling3611.5PAX6, ITGAL, ITGAM, FGF10, FGF23, MERTK
12Akt Signaling3611.4PIK3CG, LIF, ITGAL, ITGAM, FOXO1, FGF10
13Endothelin-1 Signaling Pathway3611.3MERTK, IL10, IL11, IL18, IL1A, IL1B
14Phospholipase-C Pathway3611.2KDR, CD79A, ITGAL, ITGAM, ARHGEF2, FGF10
15Rheumatoid arthritis2011.1VEGFA, ITGAL, MMP1, IL11, IL18, IL1A
16MIF Mediated Glucocorticoid Regulation3611.1LIF, IL10, IL11, IL18, IL1A, IL1B
17ERK5 Signaling3611.0KDR, FGF10, FGF23, IL2, IL2RA, IL3
18Jak-STAT signaling pathway2011.0PIK3CG, CNTF, LEP, IL10, IL11, IL2
19PEDF Induced Signaling3611.0SERPINF1, LIF, IL10, IL11, IL18, IL1A
20IL-6 Pathway3611.0IL10, IL11, IL18, IL3, IL4, IL5
21Antioxidant Action of Vitamin-C3611.0MYO7A, LIF, KDR, FGF10, FGF2, FGF23
22IP3 Pathway3611.0KDR, CD79A, FGF10, FGF2, FGF23, IL2
23RAR-Gamma-RXR-Alpha Degradation3611.0LIF, UBE3A, IL11, IL2, IL3, MAPK14
24Transcription Role of VDR in regulation of genes involved in osteoporosis1010.9VDR, BGLAP, CGA, AR, IL1A, IL1B
25Transcription_Role of VDR in regulation of genes involved in osteoporosis4110.9VDR, BGLAP, CGA, AR, IL1A, IL1B
26Molecular Mechanisms of Cancer3610.9PIK3CG, LRP5, RARA, LIF, KDR, FZD4
27Hematopoietic cell lineage2010.8CD36, CD9, CD55, ITGAM, MME, IL11
28Malaria2010.7SELE, SELP, CD36, CD40LG, ITGAL, IL10
29STAT3 Pathway3610.7LIF, CDKN1A, IL10, IL11, IL18, IL1A
30JAK-STAT Pathway3610.6KDR, FGF10, FGF2, FGF23, MERTK, IL10
31PAK Pathway3610.6MYO7A, LIF, KDR, FGF10, FGF2, FGF23
32Breast Cancer Regulation by Stathmin13610.5ARHGEF2, FGF10, FGF2, FGF23, GNAI1, GNAI3
33MIF Regulation of Innate Immune Cells3610.5LIF, IL10, IL11, IL18, IL1A, IL1B
34DHA Signaling3610.4SERPINF1, KDR, FOXO1, FGF10, FGF2, FGF23
35Cytokine Network3610.4IL10, IL18, IL1A, IL1B, IL2, IL3
36Selected targets of GCR-alpha1010.4LEP, CGA, FSHB, CDKN1A, INS, IL1B
37Chagas disease (American trypanosomiasis)2010.3PIK3CG, SERPINE1, IL10, IL1B, IL2, IL6
38PGC1Alpha Pathway3610.3IL11, IL18, IL1A, IL1B, IL1R1, IL2
39eNOS Signaling3610.3CNGA1, CNGB1, GUCY2D, FGF10, FGF23, MERTK
40p38 Signaling3610.2LIF, KDR, FGF10, FGF2, FGF23, MERTK
41Tec Kinases Signaling3610.1ITGAL, ITGAM, FGF10, FGF2, FGF23, IL10
42MAPK Signaling3610.0KDR, ITGAL, ITGAM, FGF10, FGF2, FGF23
43PPAR Pathway3610.0ITGAL, ITGAM, FGF10, FGF2, FGF23, IL2
44MAPK Family Pathway3610.0KDR, ARHGEF2, FGF10, FGF2, FGF23, IL10
45Estrogen Pathway369.9KDR, UBE3A, FGF10, FGF2, FGF23, MERTK
46TGF-Beta Pathway369.9KDR, FGF10, FGF2, FGF23, IL10, IL11
47NF-KappaB (p50-p65) Pathway369.8KDR, FGF10, FGF2, FGF23, IL1A, IL1B
48JNK Pathway369.8KDR, FGF2, IL1R1, IL2, IL2RA, IL2RB
49Apoptotic Pathways in Synovial Fibroblasts369.4KDR, FGF10, FGF2, FGF23, IL2, IL2RA
50Pancreatic Adenocarcinoma368.2KDR, CDKN1A, CDKN2A, MMP1, MMP9, ARHGEF2

Compounds for genes affiliated with Blindness

Sources:
32Novoseek , 9DrugBank, 18HMDB, 34PharmGKB, 42Tocris Bioscience
See all sources

Compounds related to blindness according to GeneDecks:

(show top 50)    (show all 598)
idCompoundScoreTop Affiliating Genes
1estrogen32 16.8LRP5, COG2, VWF, GCG, RBP4, SERPINC1
2serine32 16.7PIK3CG, PDE4A, CNR1, CNTF, VWF, GCG
3phospholipid32 14.4COG2, PDE4A, VWF, RCVRN, RBP4, LPL
4potassium32 9 18 9 17.2PIK3C2A, COG2, PDE4A, REN, CNGB1, CNTF
5aspirin32 34 18 15.9COG2, PDE4A, CNR1, VWF, SELE, SELP
6h2o232 13.8PIK3CG, PDE4A, CNTF, VWF, SEPP1, VIP
7vegf32 13.0PIK3C2A, PIK3CG, PDE4A, REN, CNTF, VWF
8homocysteine32 18 13.9PIK3C2A, COG2, VWF, SELE, SELP, SERPINC1
9endotoxin32 12.5LIF, PAFAH1B1, CHKB, SAA1, SAA4, ITGAL
10kininogen32 12.4REN, VWF, SELP, SERPINC1, SERPINE1, CLU
11mannitol32 9 9 14.0SELP, SCT, CHKB, XDH, B2M, CGA
12sialic acid32 11.9RBP4, SERPINA7, CLU, CFH, FSHB, CD79A
13guanidine hydrochloride32 11.8CNTF, VWF, LPL, BGLAP, CHKB, GSR
14agarose32 11.7CNBP, VWF, SERPINA7, LIF, CLU, CHKB
15carbachol32 9 9 13.7GCG, SCT, CGA, CFTR, IL11, CCK
16bromocriptine32 9 9 13.7PIK3C2A, VIP, HTR1A, HTR2A, HTR2C, GNRH1
17adenine32 9 18 9 14.7VWF, LEP, UGT1A1, MTHFR, XDH, CDKN2A
18enalapril32 9 9 13.6REN, SERPINE1, VIP, MME, IL10, APOA1
19gemfibrozil32 9 9 13.6PIK3C2A, COG2, LPL, CHKB, CETP, INS
20clopidogrel32 34 9 18 9 15.5SERPINC1, VASP, P2RY12, CD40LG, F10, HMGCR
21phenylephrine32 9 18 9 14.4LPL, LIF, LEP, CGA, CGB5, AR
22citrate32 11.3PIK3C2A, SELP, VDR, CHGA, CHKB, CFTR
23inositol32 11.3PDE4A, LPL, CHGA, CHRM3, CD79A, GNAI1
24polyethylene glycol32 11.3SELE, SERPINC1, VIP, CHKB, MPO, CD9
25rantes32 11.3SELE, SELP, VIP, LIF, SCT, CD40LG
26cyclophosphamide32 34 9 9 14.3ITGAL, F9, F8, TPMT, LTF, TAC1
27paroxetine32 34 9 9 14.2LEP, CHRM3, MAOA, HTR1A, HTR1B, HTR2A
28progestin32 11.2SERPINC1, VEGFA, LIF, KDR, CGA, CGB5
29lactose32 9 9 13.1SELE, CFTR, CD40LG, MLXIPL, FGF2, IL2RB
30raloxifene32 9 9 13.0VWF, SERPINC1, SERPINA7, SERPINE1, VDR, BGLAP
31methylcellulose32 11.0LIF, FGF2, IL11, IL1A, IL3, IL4
32alendronate32 9 9 12.9VDR, BGLAP, PAX5, CD36, MMP1, IL11
33rituximab32 34 9 9 13.9PAX5, CD79A, CD40LG, CD55, IL10, IL1R1
34methotrexate32 34 42 9 9 14.8PIK3C2A, SELE, SERPINE1, LEP, CHKB, MTHFR
35salicylic acid32 10.8PIK3CG, CNR1, SERPINA7, VDR, XDH, CFTR
36egcg32 10.6PIK3CG, UGT1A1, IL1A, MAPK14, CCL5, IGFBP3
37suramin32 9 9 12.5VIP, VEGFA, KDR, CFTR, CD79A, FGF2
38levamisole32 9 9 12.4CDKN3, IL18, IL2, IL2RA, IL2RB, IGHE
39quercetin32 42 9 18 9 14.2PIK3C2A, PIK3CG, SELE, UGT1A1, XDH, CFTR
40fluticasone propionate32 42 9 9 13.0SELE, BGLAP, MPO, MMP9, IL1B, IL4
41carboplatin32 34 9 9 12.7VEGFA, LIF, KDR, CHGA, MTHFR, XDH
42ly29400232 9.6PIK3C2A, PIK3CG, GCG, SELE, VEGFA, RARA
43n acetylcysteine32 9.5VWF, SELE, SELP, SERPINC1, CLU, KDR
44imatinib32 34 9 9 12.1PIK3CG, VIP, VEGFA, RARA, KDR, CDKN1A
45butyrate32 8.7RCVRN, GCG, RBP3, VDR, RARA, CLU
46gefitinib32 34 9 9 11.6PIK3CG, GCG, SELP, VEGFA, KDR, CDKN1A
47pdtc32 8.4PIK3CG, SELE, XDH, CDKN1A, MMP1, MMP9
48mg 13232 42 9.2PIK3CG, VDR, RARA, KDR, CFTR, CDKN1A
49resveratrol32 9 18 9 11.0PIK3CG, VEGFA, VDR, XDH, CDKN1A, MMP9
50paclitaxel32 34 9 9 10.9PIK3CG, VEGFA, RARA, LIF, CLU, KDR

GO Terms for genes affiliated with Blindness

Sources:
12Gene Ontology
See all sources

Cellular components related to blindness according to GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1plasma membraneGO:00588618.8HTR1B, HRAS, HRH1, HRH2, ESR1, GHR
2extracellular regionGO:00557616.9PLIN2, TF, TFRC, DNASE1, TAC1, OXT
3extracellular spaceGO:00561516.0FGF10, CCL4, CCL2, CCL11, CCL3, CCK
4integral to plasma membraneGO:00588715.0HLA-B, PDGFRA, RHO, LTB4R, EDNRA, ABCA4
5photoreceptor outer segmentGO:00175012.5CNGB3, PCDH15, MYO7A, USH1C, IQCB1, INHA
6secretory granuleGO:03014111.2PLAT, PLA2G2A, LTF, ACPP, ELANE, TF
7platelet alpha granule lumenGO:03109310.5PF4, PDGFB, EGF, TIMP1, TGFB3, KNG1

Biological processes related to blindness according to GeneDecks:

(show all 36)
idNameGO IDScoreTop Affiliating Genes
1visual perceptionGO:00760120.7ZNF513, LRAT, CNGA1, CNGA3, CNGB1, CNGB3
2small molecule metabolic processGO:04428116.3PIK3C2A, PIK3CG, LRAT, GCG, LPL, CHKB
3response to stimulusGO:05089614.2ZNF513, LRAT, CNGA1, CNGB1, RDH12, RDH5
4G-protein coupled receptor signaling pathwayGO:00718613.7PIK3CG, GCG, VIP, CHRM3, MLN, MLNR
5blood coagulationGO:00759613.3PIK3CG, VWF, SELP, SERPINC1, SERPINE1, VEGFA
6positive regulation of cell proliferationGO:00828412.7LRP5, CNBP, CNTF, VIP, VEGFA, RARA
7cell-cell signalingGO:00726712.6CGA, MLN, GUCA1B, AR, INHA, INS
8signal transductionGO:00716512.4PDE4A, CNGA3, CNGB3, CNTF, RCVRN, GCG
9response to drugGO:04249312.3PDE4A, REN, SERPINA7, LPL, BGLAP, UGT1A1
10inflammatory responseGO:00695412.1PIK3CG, SELE, SELP, CHI3L1, CD40LG, ITGAL
11platelet activationGO:03016812.0PIK3CG, VWF, SELP, SERPINE1, VEGFA, CLU
12agingGO:00756811.9CNR1, SERPINA7, SERPINF1, VDR, IL1B, FAS
13elevation of cytosolic calcium ion concentrationGO:00720411.8SAA1, CD55, IL1B, IL2, CCKBR, F2RL1
14regulation of blood pressureGO:00821711.6LRP5, REN, LEP, CHGA, ATP1A2, CALCA
15photoreceptor cell maintenanceGO:04549411.6RDH12, PCDH15, USH1G, USH1C, USH2A, CLRN1
16positive regulation of transcription from RNA polymerase II promoterGO:04594411.5LRP5, CNBP, SERPINE1, VEGFA, VDR, RARA
17negative regulation of inflammatory responseGO:05072811.5SERPINC1, SERPINF1, SAA1, IL2, APOA1, APOE
18response to lipopolysaccharideGO:03249611.5CNR1, SELE, SELP, UGT1A1, MMP9, FGF10
19platelet degranulationGO:00257611.4VWF, SELP, SERPINE1, VEGFA, CLU, CD36
20positive regulation of MAPK cascadeGO:04341011.4CNTF, LIF, KDR, LEP, CD36, AR
21response to ethanolGO:04547111.2CNR1, RBP4, BGLAP, MMP9, IL4, MAOB
22positive regulation of phosphatidylinositol 3-kinase cascadeGO:01406811.2CNTF, SELP, KDR, UBE3A, INS, CCL5
23positive regulation of macrophage derived foam cell differentiationGO:01074411.1LPL, CD36, APOB, PLA2G10, PLA2G2A, PF4
24female pregnancyGO:00756511.1LEP, FSHB, IL1RN, IL4, AMBP, GNRH1
25positive regulation of ERK1 and ERK2 cascadeGO:07037411.1GCG, KDR, CHI3L1, FGF10, FGF2, FGF23
26anti-apoptosisGO:00691611.1CERKL, MPO, CD40LG, FOXO1, IL10, IL1A
27response to estrogen stimulusGO:04362711.1SERPINE1, BGLAP, ARSB, FAS, CCL5, F7
28response to hypoxiaGO:00166610.9VEGFA, LEP, MMP9, IL18, IL1A, IL1B
29negative regulation of apoptotic processGO:04306610.9PIK3CG, GCG, SERPINE1, VEGFA, CLU, CLN3
30cell surface receptor signaling pathwayGO:00716610.9LAG3, SAG, CD36, INHA, MERTK, IL1R1
31negative regulation of cell proliferationGO:00828510.8VDR, LIF, MXD4, CDKN1A, CDKN2A, CDKN3
32response to glucocorticoid stimulusGO:05138410.7SERPINF1, SERPINE1, BGLAP, IL10, IL1B, IL1RN
33positive regulation of peptidyl-tyrosine phosphorylationGO:05073110.7VEGFA, LIF, CD36, INS, FGF10, IL11
34positive regulation of mitosisGO:04584010.6LRP5, INS, IL1A, IL1B, IGF2, IGF1
35positive regulation of MAP kinase activityGO:04340610.2PIK3CG, VEGFA, HTR2A, GH1, ERBB2, TNF
36positive regulation of protein kinase B signaling cascadeGO:05189710.0PIK3CG, CHI3L1, INS, CCL3, IGF2, IGF1

Molecular functions related to blindness according to GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00551520.0SOST, NHLRC1, PGR, PECAM1, ZSWIM7, RGR
2protein homodimerization activityGO:04280313.3ABCG1, ABCD1, KLHL7, NDP, SHBG, PDGFRA
3hormone activityGO:00517912.0GCG, VIP, SCT, LEP, CGA, FSHB
4growth factor activityGO:00808311.2LIF, LEP, INHA, FGF10, FGF2, FGF23
5drug bindingGO:00814411.0CYP2D6, PPARG, PPARA, ABP1, ACE, TLR7
6receptor bindingGO:00510210.8POMC, DPP4, CRH, NRG1, HLA-B, GLA
7cytokine activityGO:00512510.6IFNB1, ADIPOQ, CSF3, CSF2, CSF1, IFNG

Sources for Blindness

2CDC
11FMA
18HMDB
19ICD9CM
20KEGG
24MeSH
25MGI
27NCIt
28NDF-RT
31NINDS
32Novoseek
33OMIM
35PubMed
36QIAGEN
43UMLS